Freeline Therapeutics Holdings PLC ADR (FRLN): Price and Financial Metrics

Freeline Therapeutics Holdings PLC ADR (FRLN): $0.60

-0.02 (-2.67%)

POWR Rating

Component Grades













Add FRLN to Watchlist
Sign Up

Industry: Biotech



in industry

FRLN Stock Price Chart Interactive Chart >

Price chart for FRLN

FRLN Price/Volume Stats

Current price $0.60 52-week high $1.29
Prev. close $0.61 52-week low $0.46
Day low $0.55 Volume 193,196
Day high $0.62 Avg. volume 142,894
50-day MA $0.56 Dividend yield N/A
200-day MA $0.75 Market Cap 38.83M

Freeline Therapeutics Holdings PLC ADR (FRLN) Company Bio

Freeline Therapeutics Holdings Plc operates as holding company whose subsidiaries provide biotechnology services. It develops gene therapies for bleeding and other debilitating disorders. The company was founded by Markus Hörer and Amit Nathwani on April 3, 2020 and is headquartered in Stevenage, the United Kingdom.

FRLN Latest News Stream

Event/Time News Detail
Loading, please wait...

FRLN Latest Social Stream

Loading social stream, please wait...

View Full FRLN Social Stream

Latest FRLN News From Around the Web

Below are the latest news stories about FREELINE THERAPEUTICS HOLDINGS PLC that investors may wish to consider to help them evaluate FRLN as an investment opportunity.

Freeline Publishes Preclinical Proof-of-Concept Data for FLT190, its AAV Gene Therapy Candidate for Fabry Disease, in the Nature Journal Gene Therapy

Data show increased enzyme activity and reduction of harmful substrate, an established biomarker of efficacy in Fabry disease, in key tissues and organs FLT190 currently being investigated in MARVEL-1 Phase 1/2 clinical trial LONDON, Jan. 19, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced the publication of preclinical proof-of-concept data for its gene therapy candidate for Fabry disease, FLT190, in the Nature journal Gene Therapy. Fabry disease is a

Yahoo | January 19, 2023

Freeline Reports December 2022 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

LONDON, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) today announced that on December 30, 2022, the Company granted four newly hired employees non-statutory options to purchase an aggregate of 48,900 of the Company’s ordinary shares. The awards were granted as an inducement material to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were approved by an independent subcommittee of the remuneration

Yahoo | January 5, 2023

We're A Little Worried About Freeline Therapeutics Holdings' (NASDAQ:FRLN) Cash Burn Rate

We can readily understand why investors are attracted to unprofitable companies. For example, although made...

Yahoo | December 31, 2022

Freeline Receives Approval to Transfer to Nasdaq Capital Market

LONDON, Nov. 29, 2022 (GLOBE NEWSWIRE) -- Freeline Therapeutics Holdings plc (Nasdaq: FRLN) (the “Company” or “Freeline”) today announced that it received approval from the Nasdaq Stock Market LLC (“Nasdaq”) to transfer the listing of its American Depositary Shares (“ADSs”) representing ordinary shares of the Company from The Nasdaq Global Select Market to The Nasdaq Capital Market. The transfer will be effective at the opening of business on November 30, 2022. The Company will continue to trade

Yahoo | November 29, 2022

Freeline Therapeutics Stops Further Development On Hemophilia Program, Cuts Workforce

Freeline Therapeutics Holdings plc (NASDAQ: FRLN) has decided to focus its resources on FLT201 in Gaucher disease and FLT190 in Fabry disease. The company will stop investment in further development of FLT180a without a partner. Additionally, Freeline announced updated data from the two patients treated in the first cohort from the MARVEL-1 Phase 1/2 trial of FLT190 at a dose of 7.5e11 vg/kg. People with classic Fabry disease have little to no functional α-Gal A enzyme. Data exhibited elevated α

Yahoo | November 15, 2022

Read More 'FRLN' Stories Here

FRLN Price Returns

1-mo 23.79%
3-mo -21.05%
6-mo -32.58%
1-year -48.72%
3-year N/A
5-year N/A
YTD 26.29%
2022 -76.01%
2021 -89.16%
2020 N/A
2019 N/A
2018 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6803 seconds.